Prasugrel Could Avoid More Restrictive REMS Options, Lilly Hints

Should a risk management and evaluation strategy accompany approval of Lilly's anti-platelet drug prasugrel, the product may escape the most burdensome REMS options, Lilly hinted during its July 24 earning call